SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced the pricing of its upsized
Results with next-generation cardiac myosin inhibitor suggest a potentially disease-modifying therapy in non-obstructive hypertrophic cardiomyopathy HRS/BHB-1893 treatment resulted in rapid and sustained reductions in key biomarkers, structural remodeling and meaningful improvements in symptoms
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen with minimal to no titration necessary HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular outflow tract
Appointment strengthens medical leadership as company advances development of BHB-1893 Company progressing toward planned initiation of a global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026 SAN FRANCISCO, March 26, 2026: Braveheart Bio, a clinical-stage biotechnology company
SAN FRANCISCO, February 23, 2026: Braveheart Bio, a clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that it will participate in the TD Cowen 46th Annual Health Care Conference taking place March 2-4, 2026, in
Marc Evanchik promoted to Chief Scientific Officer to lead clinical development, research and scientific strategy Brittany de Temple joins as Senior Vice President of Development Operations to prepare for expanded clinical operations Company advancing toward planned initiation of a global Phase 3
San Francisco, CA, Jan. 6, 2026: Braveheart Bio, a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy and related conditions, today announced that the company will participate in the 44 th Annual J.P.
